報價延遲最少15分鐘:2025/05/31 15:59 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.21/0.03
|
|
企業價值
830.09M
|
| 資產負債 |
|
每股賬面淨值
3.13
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
297.20M
|
|
每股收益
3.20
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 15:59 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib),a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. |